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Abstract 
Background 
Production of the chemokine CCL2 by cells of the neurovascular unit (NVU) drives critical 
aspects of neuroinflammation. Suppression of CCL2 therefore holds promise in treating 
neuroinflammatory disease. Accordingly, we sought to determine if the compound bindarit, 
which inhibits CCL2 synthesis, could repress the three NVU sources of CCL2 most 
commonly reported in neuroinflammation – astrocytes, microglia and brain microvascular 
endothelial cells (BMEC) – as well as modify the clinical course of neuroinflammatory 
disease. 
Methods 
The effect of bindarit on CCL2 expression by cultured murine astrocytes, microglia and 
BMEC was examined by quantitative reverse transcription polymerase chain reaction (qRT-
PCR). Bindarit action on mouse brain and spinal cord in vivo was similarly investigated by 
qRT-PCR following LPS injection in mice. And to further gauge the potential remedial 
effects of bindarit on neuroinflammatory disease, its impact on the clinical course of 
experimental autoimmune encephalomyelitis (EAE) in mice was also explored. 
Results 
Bindarit repressed CCL2 expression by all three cultured cells, and antagonized upregulated 
expression of CCL2 in both brain and spinal cord in vivo following LPS administration. 
Bindarit also significantly modified the course and severity of clinical EAE, diminished the 
incidence and onset of disease, and evidenced signs of disease reversal. 
Conclusion 
Bindarit was effective in suppressing CCL2 expression by cultured NVU cells as well as 
brain and spinal cord tissue in vivo. It further modulated the course of clinical EAE in both 
preventative and therapeutic ways. Collectively, these results suggest that bindarit might 
prove an effective treatment for neuroinflammatory disease. 
Keywords 
CCL2, Neuroinflammation, Blood-brain barrier, Neurovascular unit, Brain microvascular 
endothelial cells, Astrocytes, Microglia 
Background 
The chemokine CCL2 (formerly called MCP-1) is a critical mediator of neuroinflammation in 
a myriad of diseases states, including multiple sclerosis (MS) and its animal model 
experimental autoimmune encephalomyelitis (EAE) [1], HIV-1 encephalitis [2], Guillain-
Barré Syndrome [3], Alzheimer’s disease [4], ischemia [5], neurotrauma [6], epilepsy [7], 
neurogenic hypertension [8] and alcoholism [9]. While its precise mechanisms of action 
remain to be elaborated, among CCL2’s widely recognized effects are disruption of the 
blood-brain barrier (BBB) [10-12] and stimulated migration of mononuclear leukocytes into 
the central nervous system (CNS) [13-17]. 
These actions and pathogenic role, along with the fact that constitutive expression of CCL2 in 
the healthy central nervous system is severely limited [18], render CCL2 an ideal target for 
therapeutic intervention in neuroinflammatory disease [17,19,20]. Indeed, there is already 
strong suggestion that pharmacological suppression of CCL2 expression [21,22], 
oligomerization [23,24] or binding to its cognate receptor, CCR2 [25,26], can mitigate 
aspects of EAE. Pharmacologic blockade of CCL2 binding to glycosaminoglycans (GAGs) 
has also been reported to antagonize an autoimmune inflammatory condition of the neural 
retina, experimental autoimmune uveitis [27]. 
While highly effective in moderating neuroinflammation experimentally, many 
pharmacological agents that abrogate CCL2 expression and/or activity have nevertheless 
failed clinically. This disappointing performance in clinical trials might stem, in part, from 
overly broad suppression of microglia and astrocytes, a potential caveat that could curtail 
beneficial action of these cells in resolving neuroinflammation [28,29], as well as redundancy 
of chemokine binding sites and targets [30,31]. An alternative approach that more selectively 
targets CCL2 synthesis might therefore hold therapeutic promise in the treatment of human 
neuroinflammatory disease. 
An attractive candidate in this regard is the well-characterized compound 2-((1-benzyl-
indazol-3-yl) methoxy)-2-methyl propionic acid (bindarit) [32]. A small, synthetic indazolic 
derivative that preferentially inhibits transcription of the monocyte chemoattractant subfamily 
of CC chemokines (MCP-1/CCL2, MCP-2/CCL8 and MCP-3/CCL7) [33], bindarit has 
shown clinical efficacy in a broad array of experimental inflammatory, autoimmune and 
vascular disorders involving peripheral organ beds [34-38], as well as success in recent 
clinical trials for diabetic nephropathy [39] and lupus nephritis [40]. Such efficacy has been 
associated with bindarit’s ability to interfere with monocyte recruitment, which is also a 
critical feature in neuroinflammatory disease [13-17]. 
Given this clinical history of bindarit suppressing various examples of peripheral 
inflammation, we investigated its effect on expression of CCL2 in culture by the three cell 
types that represent the most frequently reported CNS sources of this chemokine during 
neuroinflammation: astrocytes, microglia and brain microvascular endothelial cells (BMEC). 
These cells serve as integral components of the neurovascular unit (NVU) [41] and, via their 
expression of CCL2, can impact the BBB and course of neuroinflammatory disease [42,43]. 
As a complement to these culture studies, the ability of bindarit to suppress LPS induction of 
CNS CCL2 expression in vivo was well determined. And to gauge bindarit’s potential clinical 
efficacy, its effect on EAE, a prototypical neuroinflammatory disease [44,45], was also 
examined. Results indicate bindarit significantly suppressed CCL2 gene expression in 
culture, as well as blunted lipopolysaccharide (LPS)-induced expression of CCL2 in the CNS. 
It also inhibited various facets of clinical EAE, and showed signs of promoting disease 
recovery. Collectively, these data suggest that bindarit might offer promise, either alone or in 
conjunction with other therapies, in the treatment of human neuroinflammatory disease. 
Methods 
Reagents 
All reagents and antibodies were purchased from Sigma-Aldrich (St. Louis, MO, USA), 
unless specified otherwise. Bindarit was synthesized by and obtained from Angelini 
(Angelini Research Center-ACRAF, Italy). MOG peptide35-55 was synthesized by the WM 
Keck Biotechnology Resource Center at Yale University, New Haven, CT, USA. 
Preparation of bindarit 
For experiments with cultured cells, a stock solution of 100 mM bindarit was prepared in 
dimethyl sulfoxide (DMSO), and dilutions (50, 100, 300 and 500 μM) of the DMSO stock 
were made in culture medium. For in vivo experiments, bindarit was prepared as a suspension 
in 0.5% methylcellulose (MTC) at a concentration of 20 mg/ml as previously described [37]. 
Mice 
C57BL/6 mice were obtained from the Charles River Laboratories, Inc. (Wilmington, MA, 
USA). All animal studies were performed, and CO2-mediated euthanasia carried-out, 
according to the Animal Care and Guidelines of the University of Connecticut Health Center 
(Animal Welfare Assurance #A3471-01). 
Isolation and culture of mouse astrocytes and microglia 
Brain tissue obtained from mice at postnatal days 2 to 3 was used as the source of astrocytes 
and microglia. After decapitation, brains were removed immediately and separate astrocyte 
and microglial cultures prepared following a modified version of the protocol described by 
Ge and Pachter [46]. Cerebral cortices were first cut into small pieces (approximately 1 mm), 
and the minced tissue incubated in dissecting medium (Hank’s Balanced Salt Solution, from 
Gibco/BRL, Rockville, MD, USA), containing 0.5% glucose, 0.7% sucrose, 20 mM: 
hydroxyethyl piperazineethanesulfonic acid (Hepes) (pH 7.4) with 0.03% trypsin at 37°C for 
20 to 30 minutes. The tissue extract was then centrifuged at 1000 × g for 5 minutes and the 
resulting pellet washed and resuspended in astrocyte culture medium (Earl’s Modified Eagle 
Medium, from Gibco/BRL) containing 10% fetal bovine serum, 10% horse serum, 2 mM 
glutamine, 20 mM D-glucose, 4 mM sodium bicarbonate, 100 μg/ml penicillin and 100 μg/ml 
streptomycin. The tissue was mildly triturated to produce a single cell suspension, and the 
dissociated cells plated onto tissue culture flasks (T-75 cm
2
) coated with poly-lysine (BD 
Biosciences, Bedford, MA, USA). Cultures were maintained up to 1 week in plating medium 
in a humidified atmosphere (5% CO2) at 37°C. After this time, cultures were shaken at 200 
rpm for 2 hr at 4°C, and supernatants containing dislodged microglia collected. Supernatant 
material was then centrifuged at 1000 × g for 5 minutes to pellet microglia. Microglia were 
then resuspended in microglia culture medium (Dulbecco’s modified Eagle Medium, from 
Gibco-BRL) supplemented with 10% heat-inactivated fetal calf serum, 100 μg/ml penicillin 
and 100 μg/ml streptomycin) and cultured in a 24-well plate. Following removal of microglia 
from the initial mixed glial cultures, the latter were shaken for an additional 18 hr at 37°C to 
remove residual neurons. The enriched astrocyte population that remained was further 
depopulated of remaining microglia by treatment with L-leucine methyl ester (LME) [47]. 
LME was dissolved in astrocyte culture medium, and the solution adjusted to pH 7.4 and 
filtered prior to adding to cultures to achieve a final concentration of 50 mM. After 90 
minutes of LME treatment, astrocyte-enriched cultures were washed thoroughly and re-
incubated with fresh astrocyte culture medium. Cell purity was determined by 
immunocytochemistry using a monoclonal anti-human glial fibrillary acid protein (GFAP) 
antibody, and cultures assessed to be ≥ 98% astrocytes (GFAP+). 
Isolation and culture of mouse brain microvascular endothelial cells  
BMEC were isolated as previously detailed by this laboratory [10,48]. Primary cultures were 
typically grown for approximately five days prior to sub-culturing for experiments. At that 
time, purity was gauged to be ≥ 98% BMEC, according to diI-acetylated LDL uptake [48]. 
BMEC also exhibited common endothelial characteristics, e.g.  CD31 and vWF 
immunostaining, plus displayed expression of the tight junction-associated proteins ZO-1 and 
occluding, found enriched at the BBB. 
Treatment of cultured cells 
To examine effects of bindarit on basal CCL2 expression, cultured microglia and BMEC 
were incubated with different concentrations of bindarit for 4 hr or exposed to 300 μM 
bindarit for different time. To gauge effects of bindarit on LPS-stimulated CCL2 expression, 
astrocytes and microglia were pretreated with 300 μM bindarit for 1 hr; then cells were 
incubated with + 100 ng/ml LPS (Escherichia coli Serotype 026:B6) for 4 or 20 hr in the 
continued presence of bindarit. After treatments, cells were extracted for RNA purification. 
Separation of brain microvessels and parenchyma 
Distinct brain microvessel and parenchymal fractions were obtained using a modification of 
the method to prepare BMEC [10,48]. In brief, after removal of the brain from the cranium, 
the meninges and big vessels were discarded, and the whole brain diced into approximately 1 
mm pieces. Brain tissue was then homogenized with a 7 mL Dounce tissue grinder 
(Kimble/Kontes, Vineland, NJ, USA) in PBS. The homogenate was then transferred to a 15 
ml conical tube and centrifuged at 400  g for 15 minutes in an Eppendorf Model 5804R 
centrifuge/A-4-44 rotor. The resulting pellet was resuspended in 18% dextran (v/v, molecular 
weight 60 000 to 90 000; USB Corporation, Cleveland, OH, USA) and centrifuged at 4,500 × 
g for 15 minutes to pellet the crude microvessel fraction. The dextran supernatant and 
floating layer of myelinated axons were separated from the crude microvessel pellet, then 
diluted 1:2 with PBS and centrifuged at 720 × g for 10 minutes to sediment the parenchymal 
fraction. Both microvessel and parenchymal fractions were washed twice with PBS to 
eliminate traces of dextran. Microvessels were further washed free of blood cells by filtering 
through a 40 μm cell strainer (Becton Dickinson Labware, Franklin Lakes, IN, USA) and 
eluting with PBS. Eluted microvessels were pelleted by centrifugation at 16,000 × g in a 
table-top microcentrifuge. 
Treatment of animals 
To determine effects of bindarit on LPS-stimulated CCL2 expression in brain and spinal cord, 
C57BL/6 female mice were given intraperitoneal (i.p.) injection of bindarit (200 mg/kg) or 
methylcellulose vehicle, once a day, for 4 consecutive days. At 30 minutes following the last 
bindarit injection, mice were given i.p. injection of LPS (5 mg/kg; Escherichia coli Serotype 
026:B6). Then, 4 hr after LPS injection, mice were euthanized and brain and spinal cord 
dissected for CCL2 mRNA and protein analysis. 
For active induction of EAE, C57BL/6 female mice were immunized with MOG35-55 peptide 
(MEVGWYRSPFSRVVHLYRNGK) of rat origin, by a modification of the method 
previously described [49]. Briefly, on day 0 female mice 7 to 9 weeks of age were injected 
subcutaneously with 150 μg of MOG peptide and 300 μg of Mycobacterium tuberculosis 
(DIFCO, Detroit, MI, USA) in complete Freund’s adjuvant (CFA) (DIFCO) into the right and 
left flank, 100 μl per site. Mice were also injected i.p. with 200 ng pertussis toxin (List 
Laboratories, Campbell CA, USA) in PBS on days 0 and 2 following the first immunization. 
Animals were monitored and scored daily for clinical disease severity according to the 
following scale: 0 = normal; 1 = tail limpness; 2 = limp tail and weakness of hind legs; 3 = 
limp tail and complete paralysis of hind legs; 4 = limp tail, complete hind leg and partial front 
leg paralysis; and 5 = death. Several disease parameters were calculated as described [49]. 
The mean day of onset was calculated by averaging the time when clinical symptoms, that is, 
a clinical score ≥ 1, were first observed for two consecutive days in each mouse. The mean 
maximum clinical score was calculated by averaging the highest score for each mouse. The 
disease index was calculated by adding the daily average clinical scores in each group, 
dividing by the mean day of onset, and multiplying by 100. In the case that an animal showed 
no disease, the day of onset was arbitrarily counted as one day after the last day of the 
experiment (for example, day 22). And the disease incidence was the fraction of mice 
experiencing EAE. 
To investigate the effects of bindarit on both the clinical course of EAE and CCL2 level 
during disease, mice were given daily i.p. injection of bindarit (or vehicle MTC) at 200 
mg/kg for three consecutive days, beginning the day before MOG immunization (day -1), 
then injections every other day till day 20. This schedule was designed to mitigate, as much 
as possible, trauma associated with daily injections at times of peak neurologic disease and 
physical compromise. 
RNA purification from cell cultures 
Total RNA was extracted from cell cultures using the RNeasy kit according to the 
manufacturer’s instructions. RNA was treated with Turbo DNAse (Ambion, Austin, TX, 
USA) according to the protocol provided by the manufacturer. RNA yield and purity were 
determined by spectrophotometry absorption at 260 and 280 nm. 
RNA purification from CNS tissue 
RNA and protein were differentially extracted from the same mouse brain and spinal cord 
samples using the AllPrep RNA/Protein kit (QIAGEN, Valencia, CA) following the 
manufacturer’s instructions. RNA was treated with Turbo DNAse (Ambion, Austin, TX, 
USA) according to the protocol provided by the manufacturer. RNA yield and purity were 
determined by spectrophotometry absorption at 260 and 280 nm. Protein level was 
determined using the Micro BCA protein assay kit (Pierce, Rockford, IL, USA), using bovine 
serum albumin as a standard. 
Reverse transcription 
cDNA was synthesized from the total RNA using a SuperScript III (Invitrogen, Carlsbad, 
CA, USA) First-strand synthesis  system for RT-PCR with a standard protocol. The resulting 
cDNA was stored at -80°C until used for further analysis. 
CCL2 RNA determination by quantitative RT-PCR 
Measurements of cDNA levels were performed by quantitative (q) RT-PCR using an ABI 
PRISM 7500 Sequence Detection System Version 1.3, and SYBR green ( AB Applied 
Biosystems, Foster sity, CA, USA) fluorescence was used to quantify relative amplicon 
amount. Separate controls included a no template-control and no reverse transcriptase-
control, and standard curves were constructed for all primers used. Cycle time (Ct) values for 
all samples were normalized to RPL-19, the housekeeping gene encoding the 60S ribosmal 
protein L19. Specifically, relative amplicon quantification was performed using the formula: 
1  Eref Ct ref / 1  Etarget Ct target   100% , with ref: RPL19; target: CCL2; E: 
primer pair efficiency; and Ct: threshold cycle.  
For all cell culture studies and in vivo LPS studies, relative CCL2 gene expression values 
(after normalization to RPL19) were expressed as percentage of control. For EAE studies, 
relative CCL2 gene expression values were designated as percentage of RPL-19 expression, 
as control CCL2 level (time-point 0) was undetectable. The primer sequences used in this 
study were as following: for mouse CCL2, 5′- GGC TCA GCC AGA TGC AGT TAA-3′ 
(forward) and 5′- CCA GCC TAC TCA TTG GGA TCA -3′ (reverse); for RPL-19, 5′- CGC 
TGC GGG AAA AAG AAG-3′ (forward) and 5′- CTG ATC TGC TGA CGG GAG TTG -3′ 
(reverse). 
CCL2 protein determination 
The level of CCL2 was measured with mouse JE/CCL2 commercial enzyme-linked 
immunoassay kit (BioSource International Inc., Camarillo, CA) according to the 
manufacturer’s instructions. 
Statistical analysis 
Statistical significance of differences between mean values of bindarit-treated cultures and 
control cultures was analyzed using a paired two-tailed t-test, while comparisons of bindarit 
treatment on LPS-treated mice were performed using a two-tailed t-test for independent 
samples. For analysis of bindarit effects on clinical EAE, a chi-squared (χ2) test was used for 
comparisons of disease incidence; a Mann-Whitney U-test was used for comparisons of 
disease index; and a two-tailed t-test for independent samples was used for comparison of 
disease onset. A P-value < 0.05 was considered significant in all cases. 
Results 
Bindarit differentially suppresses CCL2 expression by cultured CNS cells 
The effects of bindarit on cultured glial and BMEC were investigated first (Figures 1, 2, 3). 
Figure 1 shows that cultured microglia demonstrated both a dose and time dependency of 
bindarit effect on CCL2 mRNA level. Suppression of basal CCL2 mRNA was seen beginning 
with the lowest dose of 50 μM for 4 hr, amounting to nearly 75% reduction. Increasing the 
dose to 300 and 500 μM resulted in still further diminution of CCL2 mRNA to approximately 
10% and 5%, respectively, of control level. Treatment with bindarit at 300 μM for as little as 
2 hr resulted in near 60% reduction in CCL2 mRNA level, and treatment for longer times at 
this concentration resulted in suppression of CCL2 mRNA to > 90% of control level. 
Figure 1 Bindarit effects on CCL2 mRNA in cultured microglia. Microglia, prepared 
from C57BL/6 mouse brain, were incubated with bindarit at the indicated concentrations for 
4 hr (A), or exposed to 300 μM bindarit for the indicated times (B). Control cultures received 
only vehicle. Relative CCL2 RNA levels were determined by qRT-PCR, and effects of 
bindarit treatment reported as % change compared to control cultures. *P < 0.05; 
#
P < 0.01 
(compared to control at 0 concentration or 0 time of bindarit) 
Figure 2 Bindarit effects on CCL2 mRNA in cultured BMEC. Brain microvascular 
endothelial cells (BMEC), prepared from C57BL/6 mouse brain, were incubated with bindarit 
at the indicated concentrations for 4 hr (A), or exposed to 300 μM bindarit for the indicated 
times (B). Control cultures received only vehicle. Relative CCL2 RNA levels were 
determined by qRT-PCR, and effects of bindarit treatment reported as % change compared to 
control cultures. *P < 0.05; 
#
P < 0.01 (compared to control at 0 concentration or 0 time of 
bindarit) 
Figure 3 Bindarit effects on LPS-stimulated CCL2 mRNA in cultured astrocytes and 
microglia. Separate cultures of astrocytes (A) and microglia (B), prepared from C57BL/6 
mouse brain, were pre-treated with 300 μM bindarit for 1 hr, then incubated with + 100 ng/ml 
lipopolysaccharide (LPS) in the continued presence of bindarit. Astrocytes cultures were 
exposed to LPS for the indicated times to stimulate CCL2 expression. Microglial cultures 
were only exposed to LPS for 4 hr, as these highly express CCL2 even under basal 
conditions. Control cultures received only vehicle. Relative CCL2 RNA levels were 
determined by qRT-PCR, and effects of bindarit treatment reported as % change compared to 
control cultures. Brackets designate comparison between the two respective groups. *P < 
0.05; 
#
P < 0.01 
BMEC demonstrated a similar qualitative response in basal CCL2 mRNA to increasing 
bindarit concentration, but suppression was not as severe as seen with microglia (Figure 2). 
Significant reduction was not observed until 100 μM, and the maximal suppression achieved 
was about 20% that of control. The time course of bindarit action on BMEC also differed. 
Maximal suppression by 300 μM bindarit was achieved at the earliest time-point of 2 hr, 
reaching a level of approximately 20% of that of the control. Longer time-points, however, 
appeared to result in a lesser effect. It is important to reemphasize that, in the normal CNS, 
CCL2 expression is barely detectable. This would suggest that both cultured microglia and 
BMEC, possibly removed from a normally suppressive microenvironment, are in a somewhat 
activated state. 
This situation appears different for astrocytes. In this case, bindarit’s effects on constitutive 
CCL2 gene expression could not be accurately assessed, as level of this chemokine’s mRNA 
in murine culture of these cells is very low. Astrocyte cultures were thus stimulated with LPS 
for different lengths of time to greatly induce CCL2 mRNA, and the effect of bindarit on this 
CCL2 induction was assayed (Figure 3A). Stimulation with 100 ng/ml LPS for both 4 hr and 
20 hr produced similar elevations in CCL2 gene expression, and bindarit treatment at 300 μM 
similarly suppressed, by 40 to 60%, the induction of CCL2 mRNA at both time-points. 
In light of bindarit’s success at mitigating induction of CCL2 in astrocytes, we next assayed 
whether it was similarly effective in preventing induction in LPS-stimulated microglia. 
Figure 3B shows that this was in fact the case, bindarit completely suppressing the induction 
and reducing CCL2 mRNA level to 15% of the control (basal) value. 
Bindarit blocks LPS-induced CCL2 expression in brain and spinal cord 
It was next investigated whether bindarit could suppress LPS-induced CCL2 expression in 
the CNS in vivo (Figure 4). In the normal, resting state, CNS CCL2 mRNA level is barely 
detectable in C57BL/6 mice [50], but is elevated 50- to 100-fold shortly after peripheral LPS 
injection [51]. Pretreatment with bindarit was nevertheless able to effectively block this 
induction both in the brain and spinal cord, by 92% and 86%, respectively. In addition to 
abrogating LPS-induction of CCL2 mRNA in the CNS, bindarit was also effective at 
reducing CCL2 protein level in both brain and spinal cord, though not to the same extent as 
mRNA. 
Figure 4 Bindarit’s effects on CCL2 mRNA and protein in brain and spinal cord 
following LPS. Mice received i.p. injection of 200 mg/kg bindarit (or vehicle) once a day for 
4 days, followed by i.p. injection of 5 mg/kg lipopolysaccharide (LPS) at 30 minutes after the 
last bindarit treatment. At 4 hr after LPS injection, brain and spinal cord were prepared for 
CCL2 mRNA (A) and protein (B) determinations. LPS + bindarit-treated brain or spinal cord 
samples were compared to corresponding samples treated with LPS + vehicle (control). *P < 
0.05; 
#
P < 0.01 
Bindarit therapeutically modifies clinical EAE 
The ability of bindarit to modify clinical EAE was examined next. Figure 5 shows that, with a 
bindarit schedule of daily injections for the first three days, and beginning at day -1, then 
injections every other day till day 20, bindarit yielded several therapeutic effects. By the 
criterion that disease is manifest when a clinical score of at least 1 is demonstrated for at least 
two consecutive days [49], bindarit delayed onset of EAE. Specifically, control mice 
developed acute disease beginning at day 8, while bindarit-treated mice did not show 
evidence of clinical disease until days 14 to 15. A second therapeutic effect observed was 
reduced disease progression and severity. Control mice showed rapid progression of EAE, 
proceeding towards a maximum mean clinical score of approximately 2.1 to 2.2 by day 9. 
Bindarit-treated mice evidenced slower progression, and only reached a maximum mean 
clinical score of 1.5. A third therapeutic effect was apparent reversal of disease course. After 
experiencing rapid onset, control mice showed a plateau in disease score typical of this 
monophasic MOG-induced EAE [52,53]. However, in marked distinction, bindarit-treated 
mice demonstrated a consistent downward trend in disease score following their delayed and 
attenuated peak in clinical presentation. A summary of the effects of bindarit treatment on 
clinical EAE is presented in Table 1. 
Figure 5 Bindarit effects on clinical experimental autoimmune encephalomyelitis (EAE). 
Mice were subject to EAE by active immunization with MOG peptide, beginning on day 0, as 
detailed in Methods. Bindarit (or vehicle) was injected i.p. at 200 mg/kg according to the 
schedule indicated, beginning at day -1 (one day before MOG immunization). Mean clinical 
score (A) and % incidence of EAE (B) were determined. EAE was diagnosed when animals 
demonstrated a clinical score > 1 for two consecutive days 
Table 1 Summary of bindarit effects on clinical experimental autoimmune 
encephalomyelitis (EAE) parameters 
Group Sick/total, 
number 
Mean day of onset
a
 Mean max clinical score Mean disease index
b
 
MTC 14/14 11.42 ± 1.76 2.43 ±0.47 163.7 ± 20.53 
BND 8/14 16.85 ± 2.17 1.52 ± 0.88 99.3 ± 10.21 
P-
value 
- <0.005 <0.001 <0.01 
Mean presented ± SD 
a
Day of onset established when clinical score ≥ for two consecutive days 
b
Disease index calculated at day 21 
We next sought to examine how bindarit modifies CCL2 expression in the brain during EAE. 
First, the temporal expression of CCL2 was determined only in MOG-immunized mice not 
receiving any bindarit, to gauge the window of opportunity during which bindarit might act. 
As seen in Figure 6, CCL2 RNA is barely detectable at the time of immunization. Its 
expression then accelerates beginning around day 9, is significantly elevated by day 14, 
rapidly declines at day 17, and reaches near basal level by day 21. Because bindarit has been 
shown to most effectively suppress stimulated, rather than basal, CCL2 expression [33,54], 
bindarit effects on CCL2 were analyzed selectively during this peak interval. Additionally, 
brain tissue was resolved into microvascular and parenchymal fractions to further identify 
targeted cell types. This resolution was deemed important, as both microvessels (BMEC) and 
parenchymal neural cells (astrocytes and microglia) have been reported as sources of CCL2 
during EAE [55-58], though microvessels only contribute < 1% to brain volume [59]. It was 
thus reasoned that parenchymal effects could overshadow possible bindarit-induced changes 
in microvascular CCL2 expression if only whole-brain levels were evaluated. Figure 7 
reveals that bindarit significantly reduced peak CCL2 expression during EAE in both 
microvascular and parenchymal fractions, in agreement with what was found in our culture 
studies. Also, bindarit did not affect CCL2 expression outside the peak window, reinforcing 
that its action appears restricted to activated cells within and outside the CNS [33,54]. 
Figure 6 CCL2 expression profile during experimental autoimmune encephalomyelitis 
(EAE). Mice were immunized with MOG peptide to induce EAE. At the indicated days post-
immunization, mice were sacrificed and CCL2 mRNA levels determined in the whole brain. 
CCL2 expression is seen to rapidly rise and fall between days 9 to 21, showing the highest 
level at day 14 
Figure 7 Effects of bindarit on CCL2 expression in central nervous system (CNS) 
fractions during experimental autoimmune encephalomyelitis (EAE). Mice were 
immunized with MOG peptide to induce EAE, and were injected with bindarit (or MTC 
vehicle) as in Figure 5. At the indicated days post-immunization, mice were sacrificed and 
CCL2 mRNA levels determined in microvascular (A) and parenchymal (B) fractions. 
Bindarit treated groups were compared to vehicle treated groups. *P < 0.01 
Discussion 
Given the success of the CCL2 synthesis inhibitor bindarit in ameliorating several animal 
disease models and human clinical conditions associated with peripheral inflammatory 
disease, initial studies were conducted to examine its effects on elements critical to 
neuroinflammatory disease. Focusing on the three main cell types responsible for CCL2 
expression during neuroinflammation, experiments revealed bindarit significantly suppressed 
CCL2 in cultured BMEC, microglia and astrocytes. Bindarit was further shown to be 
effective in vivo in two neuroinflammatory paradigms: 1) it blocked LPS induction of CCL2 
in both brain and spinal cord; and 2) it therapeutically modified the course of EAE while 
suppressing CCL2 expression in both brain microvascular and parenchymal compartments. 
As to the effects on the seminal sources of CCL2, it was critical to determine whether each 
was susceptible to bindarit, as the specific cellular pool(s) responsible for CCL2’s pathogenic 
actions during neuroninflammatory disease remain unclear [51]. While all three cell types 
responded with significant reduction in CCL2 mRNA, microglia were the most sensitive - 
experiencing > 90% diminution in this chemokine’s expression. This high sensitivity to 
bindarit holds particular significance, as microglia are widely considered the primary immune 
effector cells in the CNS [60-63], and their expression of CCL2 has been linked to monocyte 
recruitment into the CNS [64,65]. As CCL2 can also direct recruitment and proliferation of 
microglia [66-68], as well as activation of these cells [68], microglial expression of CCL2 can 
potentially support a self-sustaining cycle of neuroinflammation. Bindarit action, however, 
might effectively abrogate such a scenario. 
That bindarit also suppressed CCL2 mRNA in BMEC is noteworthy. As these cells form the 
first line of defense in the BBB [69], their expression of CCL2 might strongly influence 
incipient steps of neuroinflammation [70]. Indeed, elevated CCL2 expression by BMEC has 
been reported in MS [71] and EAE [55,56], as well as in autoimmune inflammation of the 
peripheral nervous system [3]. Furthermore, intravenously administered anti-CCL2 antibody 
blocked heightened leukocyte adhesion to pial venular endothelium in vivo in mice suffering 
acute EAE [72], as well as prevented recurring clinical episodes in a chronic relapsing EAE 
model [73], possibly by antagonizing CCL2 at the luminal endothelial surface. Supporting 
this possibility, CCL2 harbors in its C-terminal α-helix a binding site for GAGs typically 
found on the luminal endothelial surface [74], and has been shown to bind to the luminal 
surface of cultured endothelial cells and then trigger firm adhesion followed by 
transmigration of mononuclear leukocytes [75,76]. Binding of CCL2 released from BMEC in 
culture has most recently been shown to switch from the luminal to the abluminal surface 
following cytokine-induced activation [77], possibly reflecting the changing roles of this 
chemokine pool from first promoting leukocyte adhesion to later directing extravasation into 
the parenchyma. Thus, by targeting the BMEC reservoir of CCL2 during disease, bindarit 
might be able to blunt neuroinflammation at different stages. 
Bindarit action on CCL2 expression by cultured astrocytes had to be studied in the context of 
LPS stimulation, as these cells exhibit barely detectable CCL2 mRNA in culture or in situ in 
the naïve state [50,51]. Yet despite significant induction, astrocyte CCL2 mRNA was reduced 
by half or more following bindarit exposure. As astrocytes constitute the most abundant glial 
cell population in the CNS [78], suppression of their CCL2 production by bindarit in vivo 
might well exert profound influence on pathologic events. 
That bindarit could indeed act in vivo to effectively suppress neuroinflammation was evident 
in both the LPS and EAE paradigms. Injection of bindarit dramatically reduced LPS-
stimulated expression of CCL2 in both brain and spinal cord, dropping mRNA levels to near 
10% of vehicle-injected control values, while cutting protein levels approximately by half. In 
this case, the efficacy of bindarit in suppressing brain CCL2 may have been aided by the fact 
that LPS can severely disrupt the BBB [79,80], and thereby possibly facilitate bindarit entry 
into the CNS parenchyma. As CCL2 can also disrupt tight junctions leading to elevated BBB 
permeability [10-12], CCL2 generated early after LPS injection may have contributed to its 
subsequent suppression by further enabling bindarit CNS access. 
The effects of bindarit on clinical EAE suggest that bindarit exerted both preventative and 
therapeutic actions. Preventative action is indicated by the considerable delay in disease onset 
in the bindarit-treated group, as well as the reduced incidence and severity of disease 
displayed by these mice. Possible therapeutic action is conveyed by the steady decline in 
disease severity following diminished peak clinical score. Such decline was in marked 
contrast to the typical plateau in clinical score exhibited by EAE mice given vehicle. These 
results are qualitatively similar to those recently reported by Laborde et al. [81] who, 
employing a regimen of twice daily oral dosage of a novel heteroaroylphenylurea antagonist 
of CCL2 function, also described delayed disease onset and resolution of EAE symptoms. In 
the case of bindarit, however, clinical symptoms seemed to steadily remit following 
attenuated peak disease, and a reduced incidence was also noted. Both studies nevertheless 
highlight the prospect that selective targeting of CCL2 activity might prevent EAE, as well as 
reverse its course. 
The effect of bindarit on clinical EAE was accompanied by significant reduction of CCL2 
mRNA in both brain microvessel and parenchymal fractions, consistent with bindarit’s 
mechanism of action being inhibition of CCL2 transcription [33]. Reinforcing this point, 
global knockout of the CCL2 gene has been shown to similarly delay EAE onset, and reduce 
both disease incidence and severity, effects that have been attributed to absence of CCL2 
expression within the CNS compartment [81,82]. This, along with demonstration that CCL2-
deficient mice also exhibit reduced neuroinflammatory responses to peripheral LPS injection 
[83,84], underscores CCL2’s non-redundant role in neuroinflammatory disease and 
accentuates its value as a therapeutic target. Results with bindarit and EAE may further 
suggest that both microvascular and parenchymal sources of CCL2 contribute to 
pathogenesis. If this is so, it could further imply bindarit would not have to penetrate the BBB 
in order to reach at least one of its targets, BMEC. In contrast to the acute situation with LPS, 
which acts directly on the endothelium, it is reasoned that the BBB was more intact in EAE 
mice receiving bindarit, as mean disease score only reached approximately 1.5. Thus, a likely 
scenario is that bindarit also sufficiently crossed the BBB to suppress the astrocyte and/or 
microglial response as well. This lends promise that bindarit can access the CNS parenchyma 
during the early stages of neuroinflammatory disease, when BBB breakdown is not yet 
manifested. 
Conclusions 
In summary, the CCL2 synthesis inhibitor bindarit, previously shown to be highly effective in 
myriad experimental disease models as well as human conditions having inflammatory 
involvement [34-40], was observed to significantly reduce steady state and LPS-induced 
CCL2 expression in cultured microglia, BMEC and astrocytes, as well as LPS-stimulated 
CCL2 mRNA and protein levels in CNS tissue in situ. Bindarit was further effective in 
delaying, preventing and attenuating clinical EAE, and evidenced signs of possibly reversing 
disease course while also suppressing elevation of CCL2 in brain microvascular and 
parenchymal compartments. Collectively, these data are consistent with the widely proposed 
critical role for CCL2 in neuroinflammation [18-20], and suggest bindarit, by targeting cells 
of the NVU [41], might have therapeutic success in the treatment of MS and/or other human 
neuroinflammatory diseases. 
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